49.53 USD
+0.63 (+1.29%)
49.53 USD
0 (0%)
SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
SNY had positive earnings in each of the past 5 years.
In the past 5 years SNY always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.05%, SNY belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
SNY has a better Return On Equity (19.73%) than 90.63% of its industry peers.
SNY has a Return On Invested Capital of 13.84%. This is amongst the best in the industry. SNY outperforms 92.71% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 12.71%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY's Profit Margin of 20.35% is amongst the best of the industry. SNY outperforms 91.67% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 23.59%, SNY belongs to the best of the industry, outperforming 90.10% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
SNY has a Gross Margin of 71.70%. This is in the better half of the industry: SNY outperforms 77.60% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
SNY has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for SNY has been reduced compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.21, SNY belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
SNY's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. SNY outperforms 45.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.37%
2.3 Liquidity
SNY has a Current Ratio of 1.27. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY has a Current ratio of 1.27. This is in the lower half of the industry: SNY underperforms 77.08% of its industry peers.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SNY (0.94) is worse than 77.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -5.35% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
The Revenue has been growing slightly by 2.56% in the past year.
Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 3.31% on average per year.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.11% yearly.
The Revenue is expected to grow by 4.55% on average over the next years.
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.11%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.55%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.13, which indicates a very decent valuation of SNY.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
A Price/Forward Earnings ratio of 9.86 indicates a reasonable valuation of SNY.
Based on the Price/Forward Earnings ratio, SNY is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
SNY is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.13 | ||
| Fwd PE | 9.86 |
4.2 Price Multiples
97.40% of the companies in the same industry are more expensive than SNY, based on the Enterprise Value to EBITDA ratio.
90.10% of the companies in the same industry are more expensive than SNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.24 | ||
| EV/EBITDA | 5.55 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)3.63
PEG (5Y)2.18
EPS Next 2Y5.75%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.56%, which is a nice return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 6.81. SNY pays more dividend than 96.88% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.56% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
49.53
+0.63 (+1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.5%
Inst Owner Change-5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap120.31B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target63.18 (27.56%)
Short Float %0.28%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.56% |
Yearly Dividend2.2
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)1.44%
PT rev (3m)-0.86%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.38%
EPS NY rev (1m)-0.69%
EPS NY rev (3m)-1.06%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.13 | ||
| Fwd PE | 9.86 | ||
| P/S | 1.52 | ||
| P/FCF | 10.24 | ||
| P/OCF | 9.06 | ||
| P/B | 1.47 | ||
| P/tB | 11.1 | ||
| EV/EBITDA | 5.55 |
EPS(TTM)4.45
EY8.98%
EPS(NY)5.02
Fwd EY10.14%
FCF(TTM)4.84
FCFY9.77%
OCF(TTM)5.47
OCFY11.03%
SpS32.61
BVpS33.62
TBVpS4.46
PEG (NY)3.63
PEG (5Y)2.18
Graham Number58.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.37%
ROIC/WACC1.88
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year30.73%
EBIT Next 3Y13.89%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 11.13 and the Price/Book (PB) ratio is 1.47.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.